z-logo
open-access-imgOpen Access
The Role of Peroxisome Proliferator-Activated Receptors in Pulmonary Vascular Disease
Author(s) -
Rachel E. Nisbet,
Roy L. Sutliff,
C. Michael Hart
Publication year - 2007
Publication title -
ppar research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 49
eISSN - 1687-4765
pISSN - 1687-4757
DOI - 10.1155/2007/18797
Subject(s) - medicine , pathogenesis , pulmonary hypertension , receptor , peroxisome proliferator activated receptor , bioinformatics , disease , endothelial dysfunction , inflammation , nuclear receptor , transcription factor , immunology , biology , gene , biochemistry
Peroxisome proliferator-activated receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily that regulate diverse physiological processes ranging from lipogenesis to inflammation. Recent evidence has established potential roles of PPARs in both systemic and pulmonary vascular disease and function. Existing treatment strategies for pulmonary hypertension, the most common manifestation of pulmonary vascular disease, are limited by an incomplete understanding of the underlying disease pathogenesis and lack of efficacy indicating an urgent need for new approaches to treat this disorder. Derangements in pulmonary endothelial-derived mediators and endothelial dysfunction have been shown to play a pivotal role in pulmonary hypertension pathogenesis. Therefore, the following review will focus on selected mediators implicated in pulmonary vascular dysfunction and evidence that PPARs, in particular PPAR γ , participate in their regulation and may provide a potential novel therapeutic target for the treatment of pulmonary hypertension.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom